GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Purchase Of Property, Plant, Equipment

Aclaris Therapeutics (Aclaris Therapeutics) Purchase Of Property, Plant, Equipment : $-1.31 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Aclaris Therapeutics Purchase Of Property, Plant, Equipment?

Aclaris Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.44 Mil. It means Aclaris Therapeutics spent $0.44 Mil on purchasing property, plant, equipment. Aclaris Therapeutics's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.31Mil.

Compared with last quarter ($-0.08 Mil in Sep. 2023 ), Aclaris Therapeutics spent more money on purchasing property, plant, equipment in Dec. 2023 ($-0.44 Mil).

Aclaris Therapeutics Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for Aclaris Therapeutics's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Purchase Of Property, Plant, Equipment Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.61 -0.45 -0.31 -0.61 -1.31

Aclaris Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Purchase Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.11 -0.55 -0.23 -0.08 -0.44

Aclaris Therapeutics Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (Aclaris Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Purchase Of Property, Plant, Equipment
Comparable Companies
ME CDNA CSTL LDDD NVTA LAB BDSX GTH BNR FONR TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
8AT:Germany
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Website
https://www.aclaristx.com
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Executives
Joseph Monahan officer: Chief Scientific Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Kevin Balthaser officer: Chief Financial Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
James Loerop officer: Chief Business Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Douglas J. Manion officer: Pres and COO C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Neal Walker director, officer: President and CEO 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Andrew N Schiff director PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Gail Cawkwell officer: Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Frank Ruffo officer: Chief Financial Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
David N. Gordon officer: Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Kamil Ali-jackson officer: Chief Legal Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
James B. Tananbaum 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Management Iii, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939